美国保险支付方SRS政策与ASTRO模型政策的一致性
本研究比较了58家保险支付方和3家国家福利管理者的立体定向放射外科(SRS)政策与ASTRO模型政策中医疗必要指征的一致性。结果显示,所有政策均覆盖脑转移瘤、药物难治性三叉神经痛和动静脉畸形,但药物难治性运动障碍(44.4%)和癫痫(33.3%)覆盖最低;全国性支付方及近12个月内更新的政策与ASTRO模型政策一致性更高。
要点
- 所有审查的保险政策均认为SRS对脑转移瘤、难治性三叉神经痛和动静脉畸形是医疗必要的。
- 区域支付方较全国支付方更不倾向于将其他神经鞘瘤及大颅/脊柱病灶推量视为医疗必要(P<.05)。
- 近一年内更新的政策更可能覆盖癫痫、运动障碍、血管母细胞瘤、松果体肿瘤和其他神经鞘瘤。
核心结论
- ASTRO模型政策中多个SRS指征在保险政策间仍存在显著差异,但全国性支付方和近期更新政策与模型政策一致性更高。
研究设计与样本
- 研究识别了58家保险支付方和3家国家福利管理者的SRS政策,排除7家2015年后未审查或未详述个体医疗必要指征的支付方。
- 针对ASTRO模型政策中每个指征,计算认为SRS医疗必要的支付方比例,并比较全国与区域支付方、近12个月更新与更新较少政策间的差异(Fisher精确检验和χ2检验)。
主要发现
- 所有审查的保险政策均将脑转移瘤、药物难治性三叉神经痛和动静脉畸形的SRS视为医疗必要。
- 区域支付方较全国支付方更不倾向于将其他神经鞘瘤及大颅或脊柱病灶的推量视为医疗必要(P<.05)。
- 覆盖率最低的指征为药物难治性运动障碍(44.4%),其次为药物难治性癫痫(33.3%)。
- 近一年内更新的政策更可能将癫痫、运动障碍、血管母细胞瘤、松果体肿瘤和其他神经鞘瘤的SRS视为医疗必要。
关键数值与推荐
- 脑转移瘤、药物难治性三叉神经痛和动静脉畸形:所有审查政策均认为SRS医疗必要。
- 药物难治性运动障碍覆盖率44.4%,药物难治性癫痫覆盖率33.3%。
- 区域支付方对其他地方神经鞘瘤及大颅或脊柱病灶推量的医疗必要性认可度低于全国支付方(P<.05)。
临床怎么用
- 放射治疗科医生在申请SRS前可参考ASTRO模型政策中医疗必要指征,尤其针对运动障碍和癫痫等低覆盖率指征需加强沟通。
- 关注保险政策更新状态,近一年内更新的政策与ASTRO模型政策一致性更高,可能减少审批障碍。
局限性
- 排除了7家2015年后未审查或未详述个体医疗必要指征的保险支付方,可能影响样本代表性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The medical necessity of stereotactic radiosurgery (SRS) is nonuniform across insurance policies. The American Society for Radiation Oncology (ASTRO) created a model policy based on the consensus of the radiation oncology community to communicate medically necessary indications for SRS. We compared the current insurance policies for SRS with those of the ASTRO model policy. METHODS AND MATERIALS: We identified 58 insurance payers and 3 national benefits managers with SRS policies. Among these, 7 insurance payers were excluded for policies that were not reviewed after 2015 and for not detailing individual medically necessary indications. For each of the indications listed in ASTRO's model policy, we determined the proportion of payers that considered SRS medically necessary. We compared these proportions for national versus regional payers and policies updated in the last 12 months versus those updated less often using Fisher exact and χ2 tests. RESULTS: All insurance policies reviewed considered SRS as medically necessary for brain metastases, medically refractory trigeminal neuralgia, and arteriovenous malformations. Compared with national payers, regional payers were less likely to deem other schwannomas, and a boost for large cranial or spinal lesions medically necessary (P < .05). The indication with the lowest coverage was medically refractory movement disorders (44.4%), followed by medically refractory epilepsy (33.3%). However, policies that were updated within the last year were more likely to deem medical necessity for epilepsy, movement disorders, hemangioblastoma, pineal gland tumors, and other schwannomas. CONCLUSIONS: Significant discrepancy remains among insurance policies for several indications in ASTRO's model policy for SRS; however, national payers and those with recent policy updates have a greater concordance with the ASTRO model policy.
引用
- Hassanzadeh C, Roach M, Rich K, et al. Adherence of US Insurance Payer Policies to the American Society of Radiation Oncology Stereotactic Radiosurgery Model Policy. Pract Radiat Oncol. 2020. PMID: 32004704. doi:10.1016/j.prro.2020.01.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。